Gina Mauro

Treatment with pacritinib, when administered at 200 mg twice daily, had a comparable safety profile to best available therapy in patients with cytopenic myelofibrosis, including those with severe thrombocytopenia.

Luspatercept-aamt produced more durable responses compared with placebo in patients with lower-risk myelodysplastic syndrome and anemia that is refractory to or ineligible for erythropoiesis-stimulating agent therapy.

OncLive® speaks with Dr. Srdan Verstovsek on the pivotal data in myeloproliferative neoplasms, and Dr. Naval Daver on some intriguing findings in acute myeloid leukemia.

Ciltacabtagene autoleucel elicited a 97.9% objective response rate and an 82.5% stringent complete response rate in patients with relapsed/refractory multiple myeloma at a median of approximately 2 years of follow-up.

Axicabtagene ciloleucel led to a 60% improvement in event-free survival compared with standard-of-care chemotherapy as second-line treatment for patients with relapsed/refractory large B-cell lymphoma.

OncLive® speaks with Dr. Nina Shah on some practice-changing multiple myeloma abstracts, and Dr. Jacqueline Barrientos on the latest in chronic lymphocytic leukemia.

OncLive speaks with Dr. Loretta Nastoupil on some exciting non-Hodgkin lymphoma studies and Dr. Michael Pulsipher on some intriguing pediatric cancer research.

Mortality rates in patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome who were diagnosed with COVID-19 were higher compared with non-cancer populations who were infected with the virus.

Orca-T significantly improved graft-vs-host disease–free relapse-free survival and time to engraftment, significantly reduced acute and chronic GVHD, and showed a trend toward improved overall survival vs standard of care in patients with serious hematologic malignancies

Not only is the 2021 ASH Annual Meeting bursting with more than 5000 abstracts unveiling pivotal data across a range of hematologic malignancies and disorders, but the conference will be held as a hybrid format after going fully virtual in 2020.

The combination of entinostat and exemestane led to a significant improvement in progression-free survival compared with placebo and exemestane in Chinese patients with advanced hormone receptor–positive breast cancer.

The selective estrogen receptor degrader elacestrant (RAD1901) led to a 30% reduction in the risk of disease progression or death compared with standard of care in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer who previously received CDK4/6 inhibition.

The FDA has extended the review period for the new drug application for pacritinib as a treatment for adult patients with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis and severe thrombocytopenia with a baseline platelet count of 50 x 109/L.

The FDA has scheduled a meeting of the Oncologic Drugs Advisory Committee (ODAC) to review the pending biologics license application/supplemental new drug application for the combination of ublituximab and umbralisib (Ukoniq; U2) for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma.

The FDA has approved pafolacianine sodium injection (Cytalux) for adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions.

The European Commission has approved the combination of pembrolizumab and lenvatinib for the treatment of patients with advanced renal cell carcinoma.

The European Commission has granted an approval to the combination of pembrolizumab and lenvatinib for the treatment of patients with advanced or recurrent endometrial carcinoma who have disease progression on or following prior platinum-containing therapy in any setting and who are not eligible for curative surgery or radiation.

Surufatinib demonstrated a comparable health-related quality of life with placebo in patients with advanced neuroendocrine tumors.

Concurrent treatment with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia who were receiving lisocabtagene maraleucel led to measurable effects in both CAR+ and endogenous T cells, both of which were linked with improved efficacy.

T-cell inflamed gene expression profile and tumor mutational burden assessment was found to be a feasible approach to study the clinical activity of 3 pembrolizumab-based combination regimens in treatment-naïve patients with advanced non–small cell lung cancer.

Lanreotide autogel/depot administered at 120 mg every 28 days may be an appropriate treatment for patients with advanced bronchopulmonary neuroendocrine tumors.

Chemoimmunotherapy is the new frontline standard of care for patients with small cell lung cancer, and other novel agents, such as, bispecific T-cell engagers are in the pipeline and gaining momentum for those who experience disease progression.

The management of endometrial cancer, a molecularly driven malignancy with 4 distinct subtypes, has witnessed significant progress with recent regulatory approvals of checkpoint blockade alone and in combination, said Bhavana Pothuri, MD, MS.

Newer modalities are exploring ways to provide more specificity on the value of minimal residual disease negativity in acute myeloid leukemia, since currently there is little definitive action that can be taken with the marker in clinical practice, according to Naval Daver, MD.

The use of risk stratification in children and adolescent and young adult patients with synovial sarcoma is an essential approach to appropriately tailoring local and systemic therapy and avoiding overtreatment.

Fixed-dose eniluracil is being evaluated with escalating doses of capecitabine in patients with advanced, refractory gastrointestinal cancers, or in advanced GI cancers who are intolerant to fluoropyrimidine chemotherapy, as part of an open-label, phase 1b dose-escalation trial.

R. Lor Randall, MD, discusses survey results in detail and what the sarcoma community can do to overcome clinical trial enrollment barriers for adolescent and young adult patients.

Adavosertib demonstrated a 65% reduction in the risk of disease progression or death compared with active monitoring in patients with TP53-/RAS-mutant metastatic colorectal cancer following first-line chemotherapy.

Adjuvant treatment with atezolizumab led to an improvement in disease-free survival and time to locoregional and distant relapse compared with best supportive care in prespecified subgroups of PD-L1–positive patients with stage II to IIIA NSCLC, according to exploratory findings from the phase 3 IMpower010 trial.

TG-1701, a covalently bound BTK inhibitor, used as monotherapy or in combination with umbralisib and ublituximab, demonstrated promising activity and a manageable safety profile in patients with chronic lymphocytic leukemia.